Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing

Lung Cancer

Volumn 84, Issue 3, 2014, Pages 215-221

  Moskalev, Evgeny A ^a   Frohnauer, Judith ^a   Merkelbach Bruse, Sabine ^b   Schildhaus, Hans Ulrich ^b   Dimmler, Arno ^c   Schubert, Thomas ^d   Boltze, Carsten ^d   König, Helmut ^e   Fuchs, Florian ^a   Sirbu, Horia ^a   Rieker, Ralf J ^a   Agaimy, Abbas ^a   Hartmann, Arndt ^a   Haller, Florian ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c St Vincentius Hospital   (Germany)

^d Institute of Pathology   (Germany)

^e Practice for Pathology   (Germany)

Author keywords

454 massive parallel sequencing; ALK rearrangement; EML4 ALK; Molecular diagnostic; NSCLC

Indexed keywords

ANAPLASTIC LYMPHOMA RECEPTOR TYROSINE KINASE; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; EML4-ALK FUSION PROTEIN, HUMAN; ONCOPROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMPLICON; ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MASSIVE PARALLEL SEQUENCING; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; ADULT; AGED; FEMALE; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PROCEDURES; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE PROTEINS, FUSION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, RNA;

EID: 84901929258     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.03.002     Document Type: Article

References (39)

1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
3. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
4. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
5. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
6. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., Giaccone G., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013, 15:415-453.
7. Peters S., Taron M., Bubendorf L., Blackhall F., Stahel R. Treatment and detection of ALK-rearranged NSCLC. Lung Cancer 2013, 81:145-154.
8. Paik J.H., Choi C.M., Kim H., Jang S.J., Choe G., Kim D.K., et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76:403-409.
9. Sasaki T., Rodig S.J., Chirieac L.R., Jänne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010, 46:1773-1780.
10. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. J Clin Oncol 2013, 31:1105-1111.
11. Takeuchi K., Choi Y.L., Togashi Y., Soda M., Hatano S., Inamura K., et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009, 15:3143-3149.
12. Togashi Y., Soda M., Sakata S., Sugawara E., Hatano S., Asaka R., et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLOS ONE 2012, 7:e31323.
13. Perner S., Wagner P.L., Demichelis F., Mehra R., Lafargue C.J., Moss B.J., et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008, 10:298-302.
14. Soda M., Isobe K., Inoue A., Maemondo M., Oizumi S., Fujita Y., et al. A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res 2012, 18:5682-5689.
15. Dai Z., Kelly J.C., Meloni-Ehrig A., Slovak M.L., Boles D., Christacos N.C., et al. Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. Mol Cytogenet 2012, 5:44.
16. Gainor J.F., Varghese A.M., Ou S.H., Kabraji S., Awad M.M., Katayama R., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer. Clin Cancer Res 2013, 19:4273-4281.
17. Penzel R., Schirmacher P., Warth A. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. J Thorac Oncol 2012, 7:1198-1199.
18. Palmer R.H., Vernersson E., Grabbe C., Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 2009, 420:45-361.
19. Boland J.M., Erdogan S., Vasmatzis G., Yang P., Tillmans L.S., Johnson M.R., et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009, 40:1152-1158.
20. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
21. Lin E., Li L., Guan Y., Soriano R., Rivers C.S., Mohan S., et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009, 7:1466-1476.
22. Zhang X., Zhang S., Yang X., Yang J., Zhou Q., Yin L., et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010, 9:188.
23. Wang R., Pan Y., Li C., Hu H., Zhang Y., Li H., et al. The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012, 18:4725-4732.
24. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
25. Sanders H.R., Li H.R., Bruey J.M., Scheerle J.A., Meloni-Ehrig A.M., Kelly J.C., et al. Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer. Cancer Genet 2011, 204:45-52.
26. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
27. Kim H., Yoo S.B., Choe J.Y., Paik J.H., Xu X., Nitta H., et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011, 6:1359-1366.
28. Wallander M.L., Geiersbach K.B., Tripp S.R., Layfield L.J. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012, 136:796-803.
29. Laffert V.M., Warth A., Penzel R., Schirmacher P., Jonigk D., Kreipe H. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer 2013, 81:200-206.
30. Minca E.C., Portier B.P., Wang Z., Lanigan C., Farver C.F., Feng Y., et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J Mol Diagn 2013, 15:341-346.
31. Schildhaus H.U., Deml K.F., Schmitz K., Meiboom M., Binot E., Hauke S., et al. Chromogenic in situ hybridization is a reliable assay for detection of ALK rearrangements in adenocarcinomas of the lung. Mod Pathol 2013, 26:1468-1477.
32. Tuononen K., Sarhadi V.K., Wirtanen A., Rönty M., Salmenkivi K., Knuuttila A., et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed Res Int 2013, 2013:757490.
33. Mino-Kenudson M., Chirieac L.R., Law K., Hornick J.L., Lindeman N., Mark E.J., et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010, 16:1561-1571.
34. Lira M.E., Kim T.M., Huang D., Deng S., Koh Y., Jang B., et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013, 15:51-61.
35. Lipson D., Capelletti M., Yelensky R., Otto G., Parker A., Jarosz M., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012, 18:382-384.
36. Peled N., Palmer G., Hirsch F.R., Wynes M.W., Ilouze M., Varella-Garcia M., et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012, 7:e14-e16.
37. Stahel R., Peters S., Baas P., Brambilla E., Cappuzzo F., De Ruysscher D., et al. Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer 2013, 82:375-382.
38. Moskalev E.A., Stöhr R., Rieker R., Hebele S., Fuchs F., Sirbu H., et al. Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumor cell content by 454 deep sequencing. Virchows Arch 2013, 462:409-419.
39. Gainor J.F., Shaw A.T. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013, 18:865-875.